JCJames Cochran

James Cochran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James Cochran has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dysphonia following anterior cervical discectomy and fusion: a PearlDiver analysis of incidence, risk factors, and interventions

    by Nancy Deng, James Cochran, Ameer Tabbaa, Afshin Razi, Sara Abu-Ghanem

    Objective: This study aimed to determine the incidence of post-operative dysphonia following anterior cervical discectomy and fusion, identify associated risk factors and assess utilisation of diagnostic and therapeutic interventions. Methods: This retrospective cohort study analysed data from the PearlDiver Mariner Patient Records Database (2010–2022). Adults (≥18 years) undergoing primary anterior cervical discectomy and fusion without pre-existing dysphonia were included ( n = 613,978). Outcomes included incidence, risk factors (odds ratios, 95 per cent confidence intervals) and intervention rates. Results: Dysphonia occurred in 2.6 per cent of patients. Risk factors included female sex (odds ratio 1.43), age 50–64 (odds ratio 1.10), 65–79 (odds ratio 1.21), smoking (odds ratio 2.41), obesity (odds ratio 2.80), diabetes (odds ratio 1.89) and multilevel anterior cervical discectomy and fusion (odds ratio 1.20) ( p < 0.01). Diagnosis was delayed (>12 months) in 73.2 per cent. Only 52.7 per cent underwent laryngoscopy; 15.0 per cent received voice therapy. Conclusion: Post-operative dysphonia is under-recognised and undertreated. Structured screening and otolaryngology referral pathways may improve diagnosis and management.

  • Accuracy of Otolaryngology-performed Simplified Flexible Endoscopic Evaluation of Swallowing (S-FEES): A Retrospective Analysis

    by Sara Abu-Ghanem, Nancy Deng, James Alrassi, Lindsay Blank, James Cochran

    Flexible endoscopic evaluation of swallowing (FEES) and modified barium swallow study (MBSS) are considered the gold standard studies for evaluating oropharyngeal swallow. In the United States, these studies are most commonly performed by speech-language pathologists (SLPs), although internationally FEES may be performed by otolaryngologists or other providers Limited literature exists on Otolaryngologist-performed FEES without the presence of SLP in the outpatient setting. This study presents the concept of Otolaryngology simplified screen FEES (S-FEES) and its accuracy compared to SLP-performed MBSS. A retrospective chart review of adult dysphagic patients presenting to an Otolaryngology clinic was performed, identifying patients who underwent Otolaryngology-performed S-FEES and SLP-performed MBSS within 3 months of each other. Demographic information and study findings were compiled and analyzed. Reliability and predictive values were calculated for S-FEES using SLP-performed MBSS as the standard. Overall, 89 patients, 52.8% male, with a mean age of 66.7 years, met the inclusion criteria. Within the group, 57.3% of patients were identified with normal S-FEES, 51.7% with normal laryngoscopy, and 68.5% with normal MBSS. Cohen’s kappa for S-FEES and MBSS was 0.762. Otolaryngology performed S-FEES had 100% sensitivity and 85.9% specificity of detecting abnormal swallow when compared to SLP-performed MBSS. Positive and negative predictive values were 73.7% and 100%, respectively. Otolaryngology-performed S-FEES represents a streamlined application of the standard FEES protocol that can be readily incorporated into otolaryngology outpatient practice in the absence of an SLP. This simplified screen protocol demonstrated high sensitivity and negative predictive value for identifying patients who may benefit from referral for comprehensive swallowing evaluation by SLP.

  • Dysphagia Following Anterior Cervical Discectomy and Fusion: A PearlDiver Analysis of Incidence, Risk Factors, and Interventions

    by James Cochran, Nancy Deng, Ameer Tabbaa, Afshin Razi, Sara Abu-Ghanem

    Anterior cervical discectomy and fusion (ACDF) is a well-established surgical procedure, with wide variation in reported postoperative dysphagia rates (1-79%). No standardized guidelines exist for screening, diagnosis, and treatment of postoperative ACDF dysphagia. The goal of the current study is to utilize a large database of US healthcare insurance claims to investigate incidence of dysphagia post-ACDF as well as risk factors for dysphagia and interventions performed in a large patient cohort. PearlDiver database was used to identify patients without preoperative dysphagia undergoing ACDF between 2010 and 2022 and create cohorts of patients with and without postoperative ACDF dysphagia. International Classification of Disease version 9 and 10 (ICD-9 and ICD-10), and Current Procedural Terminology (CPT) codes were used to retrieve patient records. The two cohorts were compared in terms of age, gender, comorbidities, prior neck surgery, postoperative vocal fold paralysis, and dysphagia related interventions. OR with 95% CI were calculated, stratifying by various risk factors. Prevalence of various postoperative diagnoses and interventions were calculated. Of 618,170 patients undergoing primary ACDF from 2010 to 2022, 88,899 (14.4%) developed postoperative dysphagia. Females, smokers, diabetics, and obese patients had higher odds of developing post ACDF dysphagia (OR 1.14, 2.51, 2.18, 2.50 respectively). 3% of patients with post ACDF dysphagia had new postoperative vocal fold motion impairment (VFMI) versus 0.3% without dysphagia (OR 8.69). Within the dysphagia cohort,14.9% underwent laryngoscopy, 19.0% underwent MBSS, 0.80% underwent FEES, and 5.2% received swallow therapy. Dysphagia is commonly diagnosed after ACDF, with females, smokers, diabetics, and obese patients having the highest odds of diagnosis. Yet, a low percentage of patients are being referred for evaluation or treatment. Providers performing ACDF should consider screening protocols and early referral to providers offering interventions for dysphagia diagnosis and treatment.


  • Open Access

    The Use of Oxygen/Air Blender during Transoral Laser Microsurgery with Supraglottic Manual Jet Ventilation: A Safe Approach

    by Sara Abu-Ghanem, James Cochran

    Surgical fires are known, preventable, and devastating complications of transoral microlaryngeal laser surgery. Several guidelines have recommended maintaining the fraction of inspired oxygen concentration (FiO2) at or below 30% for open delivery cases. We hereby present our experience utilizing an air/oxygen gas mixing device (blender) attached to a supraglottic manual jet ventilator during transoral laser microlaryngeal surgery in three cases to control oxygen levels. Retrospective chart review of three cases and literature review. Three patients underwent microlaryngeal laser surgery and balloon dilation for the management of subglottic stenosis. All three patients were successfully ventilated throughout the procedures, and no major complications occurred intraoperatively. Two of three patients demonstrated symptomatic and clinical improvement at the first follow-up. This report demonstrates the successful use of an oxygen/air blender to reduce FiO2 to fire-safe levels of less than 30% during laser surgery of the airway using jet ventilation.

  • Aquablation, Prostatic Urethral Lift, and Transurethral Water Vapor Therapy: A Comparison of Device-Related Adverse Events in a National Registry

    by Elie Kaplan-Marans, Mariela Martinez, Andrew Wood, James Cochran, Elliot Dubowitch, Ariel Schulman

    Purpose: Aquablation, prostatic urethral lift (PUL), and transurethral water vapor therapy (TWVT) have demonstrated efficacy for the treatment of benign prostatic hyperplasia (BPH). Our objective was to describe device malfunctions and complications to help guide procedural selection and performance. Materials and Methods: The Manufacturer and User Facility Device Experience (MAUDE) database was examined for reports related to the use of these three procedures for the treatment of BPH between January 1, 2015, and July 1, 2020. Reports were evaluated for device malfunctions and surgical complications using a previously described externally validated classification system developed for the MAUDE database. Chi square analysis was used for statistical comparison between groups. Results: A total of 391 adverse events were reported: aquablation ( n = 102), PUL ( n = 132), and TWVT ( n = 157). There were 79 (78%) severe or life-threatening adverse events for aquablation vs 69 (52%) for PUL vs 24 (15%) for TWVT ( p < 0.001). There were 4 cases of rectal perforation with aquablation and 25 cases of the PUL implants needing to be removed or causing a problem with a later procedure. Blood transfusion frequencies were aquablation—32 (31%), PUL—21 (16%), and TWVT—1 (1%). The most common device malfunctions were: aquablation—motion error ( n = 8), handpiece fracture/attachment malfunction ( n = 8); PUL—device misfire ( n = 27), needle fragmentation ( n = 21); TWVT—unresolvable error message ( n = 19). Conclusions: In a national database, aquablation and PUL had noteworthy complications or device-related malfunctions such as rectal perforation and the improper placement or failed deployment of the PUL implants. Both patients and providers should be aware of potential risks when selecting these novel BPH treatments.


  • Interim performance of a non-DRE urine exosome gene signature to predict Gleason ≥7 prostate cancer on initial prostate needle biopsy from patients enrolled in a prospective observational trial.

    by Michael J. Donovan, Mikkel Noerholm, Stefan Bentink, Susan Belzer, Johan Skog, Gordon Andrew Brown, James S. Cochran, Vince O'Neill

    5064 Background: PSA and DRE are used for biopsy decisions; however, limited sensitivity and specificity have resulted in the over-diagnosis and treatment of low risk prostate cancer (PCa). Non-invasive screening tools that add predictive value for identifying high-grade, Gleason score (GS) ≥ 7, should impact the current paradigm. We sought to evaluate performance of a gene signature that differentiated GS7+ from GS6 + benign disease by evaluating patients with first-time biopsy results and gray zone PSA (4-10ng/mL) from an ongoing prospective clinical trial. Methods: 499 sequentially obtained first-catch non-DRE urine specimens (standard cups) from 15 urology practices were collected from patients presenting for biopsy. Exosomes were isolated and RNA extraction performed. RT-qPCR RNA copy numbers of ERG and PCA3, normalized to SPDEF, were measured to generate a three-gene signature, defined to yield a score discriminating GS7+ vs. GS6 and benign lesions, evaluating NPV, Sensitivity and Specificity relati...